



New IVIG Physician Request Forms

Date Effective: July 1, 2017

Background Information:

Since March 1, 2014 Diagnostic Services of Manitoba (DSM) has been utilizing an independent physician request form for intravenous immune globulin (IVIG) and subcutaneous immune globulin (SCIG). The intention was to characterize practice patterns of IVIG and SCIG use in Manitoba. It has been well received and has provided useful information in the utilization of these products.

Several discussions have been held with the stakeholders since the fall of 2016 in an effort to formulate a plan that addresses utilization of IVIG in Manitoba going forward. Stakeholders include Manitoba Health, The Office of Provincial Transplant and Transfusion Services, Blood Management Service and key experts that are currently high users of IVIG/SCIG in the fields of Immunology, Neurology, Hematology and Oncology.

Change in or New Test Procedure:

On July 1, 2017, DSM will introduce a revised version of this form as well as a new secondary form that will be required for the issue of all IVIG and SCIG in Manitoba.

- **Initial Form**-this is a revised version of the existing request form. Changes include a section for BMI and weight-based dosing as well as the ability to capture additional clinical information. This form is to be completed by the physician when IVIG is initially prescribed for adult, pediatric, inpatient and outpatients in Manitoba.
- **Follow up Form**-this is a new form that will go into effect July 1, 2017. The completion of the Follow up Form will be mandatory for all IVIG re-issues after 6 months of treatment. This form details the physician's evaluation of initial IVIG treatment and includes a section for evidenced improvement in condition.

Printed forms will be available in all blood banks and available through SAP or your local purchasing department. You may also find them at <http://bestbloodmanitoba.ca/new-ivig-physician-request-forms/>

Please note: the blood bank will not issue subsequent (after 6 months) IVIG until a completed form is received.

More information: A completion guide is included for both forms. Prescribers are encouraged to review the [Manitoba Intravenous Immune Globulin \(IVIG\) Utilization Management Program Guidelines](#).

DSM Contact Information:

Dr. Charles Musuka, DSM-TM Medical Director,
(204) 237-2471, cmusuka@dsmanitoba.ca